ArticleFrontiers in oncology2021

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.

Guoqiang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.